Stereotactic Body Therapy for Urologic Cancers—What the Urologist Needs to Know [PDF]
LifeBackground: stereotactic ablative body radiotherapy (SABR) is a disruptive radiation therapy technique which is increasingly used for the treatment of urologic cancers.
Jasamine Coles-Black +6 more
doaj +2 more sources
FUNCTIONAL ANALYTIC (IR-)REGULARITY PROPERTIES OF SABR-TYPE PROCESSES [PDF]
arXiv, 2017 The SABR model is a benchmark stochastic volatility model in interest rate markets, which has received much attention in the past decade. Its popularity arose from a tractable asymptotic expansion for implied volatility, derived by heat kernel methods.
Leif Döring +2 more
openalex +2 more sources
Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC [PDF]
Cancer Immunology, ImmunotherapyBackground Stereotactic ablative radiotherapy (SABR) is thought to activate T cell responses in patients with cancer, leading to its combination with immunotherapy and chemotherapy for treatment of non-small-cell lung cancer (NSCLC).
Chao Liu +14 more
doaj +2 more sources
Partial Stereotactic Ablative Radiotherapy Boost Before Conventional Radiotherapy (P‐SABR) for Large (> 5 cm) Unresectable Stage III Nonsmall Cell Lung Cancer [PDF]
Thoracic CancerObjective Stereotactic ablative radiotherapy (SABR) is renowned for its high local control (LC) rates. Nonetheless, for tumors that are either large in volume or in close proximity to critical organs at risk, the application of SABR to the entire tumor ...
Yun Bai +15 more
doaj +2 more sources
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma [PDF]
Clinical and Translational Radiation OncologyBackground and purpose: Stereotactic ablative body radiotherapy (SABR) is an effective treatment for localized renal cell carcinoma (RCC). However, the role of primary site SABR for locally recurrent or metastatic RCC is unclear. Here, we report outcomes
Daniel Huang +12 more
doaj +2 more sources
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol [PDF]
BMC Palliative CareBackground Emerging randomized data, mostly from phase II trials, have suggested that patients with oligometastatic cancers may benefit from ablative treatments such as stereotactic ablative radiotherapy (SABR).
David A. Palma +25 more
doaj +2 more sources
Current Oncology, 2023 Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has been a significant accumulation of clinical data to support the safety and ...
Rohit K. Raj +4 more
doaj +1 more source
Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type [PDF]
Journal of Urologic Oncology, 2023 Renal cell carcinoma (RCC) has traditionally been considered one of the most radioresistant tumors based on in vitro and clinical studies that utilized a low biologically effective dose.
Chan Woo Wee, Jaeho Cho
doaj +1 more source
Ablative Therapies for Localized Primary Renal Cell Carcinoma
Société Internationale d’Urologie Journal, 2022 Surgery with either partial or radical nephrectomy remains the standard of care for localized primary renal cell carcinoma (RCC). However, most RCCs are detected in an older age group, and some may have multiple comorbidities that preclude surgery ...
Muhammad Ali +4 more
doaj +1 more source
A spectacular tumor response of a giant axillary mass treated with SABR in a palliative scenario
Brazilian Journal of Oncology, 2021 A 67-year-old male patient with a massive left axillary metastasis from an occult primary tumor (OPT) treated by stereotactic ablative radiotherapy (SABR) is presented. The patient had no clinical response to the initial chemotherapy treatment.
Fernando Kojo Matsuura +5 more
doaj +1 more source